Addressing dosing frequency in diabetes: a simple approach to improving adherence to therapy and clinical outcomes (Q35175088)

6 August 2017

title

Addressing dosing frequency in diabetes: a simple approach to improving adherence to therapy and clinical outcomes (English)

1 reference

6 August 2017

Andrew D Morris

1

1 reference

6 August 2017

publication date

1 May 2003

1 reference

The Science of Diabetes Self-Management and Care

6 August 2017

published in

1 reference

6 August 2017

volume

29

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

440-6, 448, 450-3

1 reference

Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians' Desk Reference

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Patient compliance with antihypertensive regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Hypoglycemia is the limiting factor in the management of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

How often is medication taken as prescribed? A novel assessment technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: comparison of once daily versus twice daily regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Attitudes of primary care providers toward diabetes: barriers to guideline implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Methodological issues in diabetes research. Measuring adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Respiratory infection and coronary heart disease: progression of a paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

The Management of Diabetes Mellitus in Older Individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Factors associated with glycemic control. A cross-sectional nationwide study in 2,579 French children with type 1 diabetes. The French Pediatric Diabetes Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Predictors of glycemic control in insulin-using adults with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Adherence in diabetes: can we define it and can we measure it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

21 January 2018

Sulfonylureas in NIDDM.

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Impact of dosage frequency on patient compliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Sulfonylurea pharmacotherapy regimen adherence in a Medicaid population: influence of age, gender, and race

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F014572170302900309

10.1177/014572170302900309

21 January 2018

Identifiers

DOI

0 references

1 reference